BIOMAT Database Logo BIOMAT Database Logo

Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. 1987

O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
Department of Clinical Immunology, Huddinge Hospital, Sweden.

Bone marrow transplantation recipients who were cytomegalovirus (CMV) seropositive and/or had a CMV seropositive donor were randomized for treatment with CMV hyperimmune plasma (n = 27) or no treatment at all (n = 27). The CMV hyperimmune plasma had neutralization titers greater than 250 and enzyme-linked immunosorbent assay titers greater than 18,000. Plasma (200 mg/kg body weight) was given on four occasions (during 2 days) from day 3 to day 76 after transplantation. Patient characteristics were similar in the two groups. After transplantation, the median CMV titers increased with greater than 100% in the group receiving the CMV plasma and decreased to less than 50% in the controls (p less than 0.01). Asymptomatic CMV infections occurred in 26% of the patients in the plasma group and 33% of the controls. The frequency of patients with symptomatic CMV infections was also the same in the two groups (51% vs 33%). Three patients each in the two groups developed CMV-associated interstitial pneumonitis. Patient survival and causes of death were similar in the two groups. To conclude, no beneficial effect of CMV hyperimmune plasma was seen in patients at high risk of developing CMV infections.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012698 Serologic Tests Diagnostic procedures involving immunoglobulin reactions. Serodiagnosis,Serologic Test,Serological Tests,Test, Serologic,Tests, Serologic,Serodiagnoses,Serological Test,Test, Serological,Tests, Serological
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting

Related Publications

O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
February 1997, Bone marrow transplantation,
O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus.
April 2014, The New England journal of medicine,
O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection.
July 2021, The New England journal of medicine,
O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients.
March 1984, The American journal of medicine,
O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation.
September 1988, Journal of clinical pathology,
O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
March 1991, Bone marrow transplantation,
O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
Interim results of a multicenter trial to prevent cytomegalovirus pneumonia after allogeneic bone marrow transplantation.
February 1989, Transplantation proceedings,
O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
[Cytomegalovirus infection after bone marrow transplantation].
October 1986, Gematologiia i transfuziologiia,
O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
[Cytomegalovirus infection in bone marrow transplantation].
January 1994, Gematologiia i transfuziologiia,
O Ringdén, and P Pihlstedt, and L Volin, and J Nikoskelainen, and B Lönnqvist, and P Ruutu, and T Ruutu, and A Toivanen, and B Wahren
[Cytomegalovirus infection in bone marrow transplantation].
January 2002, Terapevticheskii arkhiv,
Copied contents to your clipboard!